Glucocorticoids and polyamine inhibitors synergize to kill human leukemic CEM cells

Aaron L. Miller, Betty H. Johnson, Rheem D. Medh, Courtney Townsend, E. Brad Thompson

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Glucocorticoids are well-known apoptotic agents in certain classes of lymphoid cell malignancies. Reduction of intracellular polyamine levels by use of inhibitors that block polyamine synthesis slows or inhibits growth of many cells in vitro. Several such inhibitors have shown efficacy in clinical trials, though the toxicity of some compounds has limited their usefulness. We have tested the effects of combinations of the glucocorticoid dexamethasone (Dex) and two polyamine inhibitors, difluoromethylornithine (DFMO) and methyl glyoxal bis guanylhydrazone (MGBG), on the clonal line of human acute lymphoblastic leukemia cells, CEM-C7-14. Dex alone kills these cells, though only after a delay of at least 24 hours. We also evaluated a partially glucocorticoid-resistant c-Myc-expressing CEM-C7-14 clone. We show that Dex downregulates ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine synthesis. Pretreatment with the ODC inhibitor DFMO, followed by addition of Dex, enhances steroid-evoked kill slightly. The combination of pretreatment with sublethal concentrations of both DFMO and the inhibitor of S-adenosylmethionine decarboxylase, MGBG, followed by addition of Dex, results in strong synergistic cell kill. Both the rapidity and extent of cell kill are enhanced compared to the effects of Dex alone. These results suggest that use of such combinations in vivo may result in apoptosis of malignant cells with lower overall toxicity.

Original languageEnglish (US)
Pages (from-to)68-81
Number of pages14
JournalNeoplasia
Volume4
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Polyamines
Dexamethasone
Glucocorticoids
Eflornithine
Adenosylmethionine Decarboxylase
Ornithine Decarboxylase
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Down-Regulation
Clone Cells
Steroids
Clinical Trials
Lymphocytes
Apoptosis
Enzymes
Growth
Neoplasms

Keywords

  • Apoptosis
  • Glucocorticoids
  • Inhibitors
  • Leukemia
  • Polyamines

ASJC Scopus subject areas

  • Cancer Research

Cite this

Glucocorticoids and polyamine inhibitors synergize to kill human leukemic CEM cells. / Miller, Aaron L.; Johnson, Betty H.; Medh, Rheem D.; Townsend, Courtney; Brad Thompson, E.

In: Neoplasia, Vol. 4, No. 1, 2002, p. 68-81.

Research output: Contribution to journalArticle

Miller, Aaron L. ; Johnson, Betty H. ; Medh, Rheem D. ; Townsend, Courtney ; Brad Thompson, E. / Glucocorticoids and polyamine inhibitors synergize to kill human leukemic CEM cells. In: Neoplasia. 2002 ; Vol. 4, No. 1. pp. 68-81.
@article{cab9adf26e3e4893a1ed9da0045715db,
title = "Glucocorticoids and polyamine inhibitors synergize to kill human leukemic CEM cells",
abstract = "Glucocorticoids are well-known apoptotic agents in certain classes of lymphoid cell malignancies. Reduction of intracellular polyamine levels by use of inhibitors that block polyamine synthesis slows or inhibits growth of many cells in vitro. Several such inhibitors have shown efficacy in clinical trials, though the toxicity of some compounds has limited their usefulness. We have tested the effects of combinations of the glucocorticoid dexamethasone (Dex) and two polyamine inhibitors, difluoromethylornithine (DFMO) and methyl glyoxal bis guanylhydrazone (MGBG), on the clonal line of human acute lymphoblastic leukemia cells, CEM-C7-14. Dex alone kills these cells, though only after a delay of at least 24 hours. We also evaluated a partially glucocorticoid-resistant c-Myc-expressing CEM-C7-14 clone. We show that Dex downregulates ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine synthesis. Pretreatment with the ODC inhibitor DFMO, followed by addition of Dex, enhances steroid-evoked kill slightly. The combination of pretreatment with sublethal concentrations of both DFMO and the inhibitor of S-adenosylmethionine decarboxylase, MGBG, followed by addition of Dex, results in strong synergistic cell kill. Both the rapidity and extent of cell kill are enhanced compared to the effects of Dex alone. These results suggest that use of such combinations in vivo may result in apoptosis of malignant cells with lower overall toxicity.",
keywords = "Apoptosis, Glucocorticoids, Inhibitors, Leukemia, Polyamines",
author = "Miller, {Aaron L.} and Johnson, {Betty H.} and Medh, {Rheem D.} and Courtney Townsend and {Brad Thompson}, E.",
year = "2002",
doi = "10.1038/sj/neo/7900208",
language = "English (US)",
volume = "4",
pages = "68--81",
journal = "Neoplasia (United States)",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Glucocorticoids and polyamine inhibitors synergize to kill human leukemic CEM cells

AU - Miller, Aaron L.

AU - Johnson, Betty H.

AU - Medh, Rheem D.

AU - Townsend, Courtney

AU - Brad Thompson, E.

PY - 2002

Y1 - 2002

N2 - Glucocorticoids are well-known apoptotic agents in certain classes of lymphoid cell malignancies. Reduction of intracellular polyamine levels by use of inhibitors that block polyamine synthesis slows or inhibits growth of many cells in vitro. Several such inhibitors have shown efficacy in clinical trials, though the toxicity of some compounds has limited their usefulness. We have tested the effects of combinations of the glucocorticoid dexamethasone (Dex) and two polyamine inhibitors, difluoromethylornithine (DFMO) and methyl glyoxal bis guanylhydrazone (MGBG), on the clonal line of human acute lymphoblastic leukemia cells, CEM-C7-14. Dex alone kills these cells, though only after a delay of at least 24 hours. We also evaluated a partially glucocorticoid-resistant c-Myc-expressing CEM-C7-14 clone. We show that Dex downregulates ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine synthesis. Pretreatment with the ODC inhibitor DFMO, followed by addition of Dex, enhances steroid-evoked kill slightly. The combination of pretreatment with sublethal concentrations of both DFMO and the inhibitor of S-adenosylmethionine decarboxylase, MGBG, followed by addition of Dex, results in strong synergistic cell kill. Both the rapidity and extent of cell kill are enhanced compared to the effects of Dex alone. These results suggest that use of such combinations in vivo may result in apoptosis of malignant cells with lower overall toxicity.

AB - Glucocorticoids are well-known apoptotic agents in certain classes of lymphoid cell malignancies. Reduction of intracellular polyamine levels by use of inhibitors that block polyamine synthesis slows or inhibits growth of many cells in vitro. Several such inhibitors have shown efficacy in clinical trials, though the toxicity of some compounds has limited their usefulness. We have tested the effects of combinations of the glucocorticoid dexamethasone (Dex) and two polyamine inhibitors, difluoromethylornithine (DFMO) and methyl glyoxal bis guanylhydrazone (MGBG), on the clonal line of human acute lymphoblastic leukemia cells, CEM-C7-14. Dex alone kills these cells, though only after a delay of at least 24 hours. We also evaluated a partially glucocorticoid-resistant c-Myc-expressing CEM-C7-14 clone. We show that Dex downregulates ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine synthesis. Pretreatment with the ODC inhibitor DFMO, followed by addition of Dex, enhances steroid-evoked kill slightly. The combination of pretreatment with sublethal concentrations of both DFMO and the inhibitor of S-adenosylmethionine decarboxylase, MGBG, followed by addition of Dex, results in strong synergistic cell kill. Both the rapidity and extent of cell kill are enhanced compared to the effects of Dex alone. These results suggest that use of such combinations in vivo may result in apoptosis of malignant cells with lower overall toxicity.

KW - Apoptosis

KW - Glucocorticoids

KW - Inhibitors

KW - Leukemia

KW - Polyamines

UR - http://www.scopus.com/inward/record.url?scp=0036147378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036147378&partnerID=8YFLogxK

U2 - 10.1038/sj/neo/7900208

DO - 10.1038/sj/neo/7900208

M3 - Article

C2 - 11922393

AN - SCOPUS:0036147378

VL - 4

SP - 68

EP - 81

JO - Neoplasia (United States)

JF - Neoplasia (United States)

SN - 1522-8002

IS - 1

ER -